Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934966 | 0.90 | TDP1 (0.54) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2789108 | 0.80 | NPC1 (0.70) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30925001 | 0.80 | NPC1 (0.70) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2149947 | 0.77 | MAPT (0.50) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL31537733 | 0.77 | MAPT (0.50) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL4473461 | 0.77 | TDP1 (0.56) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL19387230 | 0.73 | TDP1 (0.38) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2705508 | 0.72 | KDM4E (0.44) | TDP1RAB9ANPC1MAPTMAOA | |
| SCHEMBL10050666 | 0.72 | NPC1 (0.44) | TDP1RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL13934967 | 0.71 | KMT2A (0.45) | TDP1RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7060711-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-06-13 | — | — | US | disclosed |
| EP-1438307-B1 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1438307-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | Biofrontera Pharmaceuticals GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1306376-A1 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003035646-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | HTR2B, HTR1B, HTR3B | TDP1 2763/4885RAB9A 1375/4885NPC1 2335/4885 |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | HTR2B, HTR1B, HTR3B | TDP1 2763/4885RAB9A 1375/4885NPC1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.